Last reviewed · How we verify
antiperspirant
The antiperspirant developed by the University of Wisconsin, Madison is currently marketed and primarily indicated for reducing underarm wetness. A key strength is the protection provided by a key composition patent, which is set to expire in 2028. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | antiperspirant |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Reduces underarm wetness
Common side effects
Key clinical trials
- A Polymer Film Device to Treat Excessive Palmar Sweating (NA)
- Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users (NA)
- Hyperhidrosis in Patients With Amputations-Botox (PHASE1)
- F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer (PHASE3)
- Topical Antiperspirant for Hand-Foot Syndrome (PHASE2)
- Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating (NA)
- A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants (PHASE1)
- To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antiperspirant CI brief — competitive landscape report
- antiperspirant updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI